The latest price target for Atossa Therapeutics (NASDAQ:ATOS) was reported by HC Wainwright & Co. on November 13, 2024. The analyst firm set a price target for $7.00 expecting ATOS to rise to within 12 months (a possible 493.22% upside). 13 analyst firms have reported ratings in the last year.

The latest analyst rating for Atossa Therapeutics (NASDAQ:ATOS) was provided by HC Wainwright & Co., and Atossa Therapeutics maintained their buy rating.

There is no last upgrade for Atossa Therapeutics

There is no last downgrade for Atossa Therapeutics.

Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of Atossa Therapeutics, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for Atossa Therapeutics was filed on November 13, 2024 so you should expect the next rating to be made available sometime around November 13, 2025.

While ratings are subjective and will change, the latest Atossa Therapeutics (ATOS) rating was a maintained with a price target of $6.00 to $7.00. The current price Atossa Therapeutics (ATOS) is trading at is $1.18, which is out of the analyst’s predicted range.